Compare Natco Pharma with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA SUN PHARMA NATCO PHARMA/
SUN PHARMA
 
P/E (TTM) x 15.2 22.3 68.3% View Chart
P/BV x 3.0 2.6 114.4% View Chart
Dividend Yield % 1.1 0.6 184.6%  

Financials

 NATCO PHARMA   SUN PHARMA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-19
SUN PHARMA
Mar-19
NATCO PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs849679 125.1%   
Low Rs557375 148.4%   
Sales per share (Unadj.) Rs573.8121.1 473.7%  
Earnings per share (Unadj.) Rs176.013.4 1,315.8%  
Cash flow per share (Unadj.) Rs198.220.7 958.2%  
Dividends per share (Unadj.) Rs6.252.75 227.3%  
Dividend yield (eoy) %0.90.5 170.4%  
Book value per share (Unadj.) Rs842.7172.6 488.3%  
Shares outstanding (eoy) m36.502,399.26 1.5%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x1.24.4 28.2%   
Avg P/E ratio x4.039.4 10.1%  
P/CF ratio (eoy) x3.525.5 13.9%  
Price / Book Value ratio x0.83.1 27.3%  
Dividend payout %3.620.6 17.3%   
Avg Mkt Cap Rs m25,6601,264,650 2.0%   
No. of employees `0005.017.5 28.3%   
Total wages/salary Rs m3,55959,671 6.0%   
Avg. sales/employee Rs Th4,225.316,608.1 25.4%   
Avg. wages/employee Rs Th718.03,409.6 21.1%   
Avg. net profit/employee Rs Th1,295.91,833.8 70.7%   
INCOME DATA
Net Sales Rs m20,945290,659 7.2%  
Other income Rs m1,30210,255 12.7%   
Total revenues Rs m22,247300,914 7.4%   
Gross profit Rs m7,94863,076 12.6%  
Depreciation Rs m81017,533 4.6%   
Interest Rs m1935,553 3.5%   
Profit before tax Rs m8,24750,246 16.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-12,144 0.0%   
Tax Rs m1,8236,009 30.3%   
Profit after tax Rs m6,42432,093 20.0%  
Gross profit margin %37.921.7 174.9%  
Effective tax rate %22.112.0 184.8%   
Net profit margin %30.711.0 277.8%  
BALANCE SHEET DATA
Current assets Rs m23,472310,692 7.6%   
Current liabilities Rs m7,287173,396 4.2%   
Net working cap to sales %77.347.2 163.6%  
Current ratio x3.21.8 179.8%  
Inventory Days Days9299 93.1%  
Debtors Days Days88112 79.1%  
Net fixed assets Rs m18,648232,477 8.0%   
Share capital Rs m3652,399 15.2%   
"Free" reserves Rs m34,525411,691 8.4%   
Net worth Rs m30,760414,091 7.4%   
Long term debt Rs m015,226 0.0%   
Total assets Rs m43,031646,938 6.7%  
Interest coverage x43.710.0 435.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.50.4 108.3%   
Return on assets %15.45.8 264.3%  
Return on equity %20.97.8 269.5%  
Return on capital %27.410.2 269.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m11,53666,025 17.5%   
Fx outflow Rs m2,93938,610 7.6%   
Net fx Rs m8,59727,415 31.4%   
CASH FLOW
From Operations Rs m6,68821,965 30.4%  
From Investments Rs m-6,122-6,813 89.9%  
From Financial Activity Rs m-509-27,305 1.9%  
Net Cashflow Rs m66-8,442 -0.8%  

Share Holding

Indian Promoters % 52.0 63.7 81.7%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 5.1 152.8%  
FIIs % 16.6 23.0 72.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 8.3 313.3%  
Shareholders   25,395 133,026 19.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 181 Points Higher; Energy and Healthcare Stocks Witness Buying(Closing)

Indian share markets continued to trade on a positive note during closing hours but ended their session off day's high.

Related Views on News

STRIDES PHARMA SCIENCE Surges by 5%; BSE HEALTHCARE Index Up 2.5% (Market Updates)

Nov 20, 2019 | Updated on Nov 20, 2019

STRIDES PHARMA SCIENCE share price has surged by 5% and its current market price is Rs 403. The BSE HEALTHCARE is up by 2.5%. The top gainers in the BSE HEALTHCARE Index are STRIDES PHARMA SCIENCE (up 5.4%) and SUN PHARMA (up 6.9%). The top losers are TORRENT PHARMA (down 0.1%) and PROCTER & GAMBLE HEALTH (down 0.2%).

SUN PHARMA Surges by 7%; BSE HEALTHCARE Index Up 2.4% (Market Updates)

Nov 20, 2019 | Updated on Nov 20, 2019

SUN PHARMA share price has surged by 7% and its current market price is Rs 461. The BSE HEALTHCARE is up by 2.4%. The top gainers in the BSE HEALTHCARE Index are SUN PHARMA (up 6.9%) and STRIDES PHARMA SCIENCE (up 5.2%). The top losers are PROCTER & GAMBLE HEALTH (down 0.2%) and ERIS LIFESCIENCES LIMITED (down 0.2%).

SUN PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 35.3% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, SUN PHARMA has posted a net profit of Rs 15 bn (up 35.3% YoY). Sales on the other hand came in at Rs 84 bn (up 15.9% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

SUN PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Aug 6, 2019 | Updated on Aug 6, 2019

Here's an analysis of the annual report of SUN PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Nov 20, 2019 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 8-QTR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS